Pipeline2018-11-09T20:25:19+00:00

Our Pipeline

Cadent Therapeutics has developed a strong pipeline of medicines for movement-related diseases and cognitive disorders, with candidates rapidly advancing into the clinic.

Essential Tremor Program

ET is a neurological disorder characterized by uncontrollable shaking or tremor in different parts of the body, including the head, arms, hands, neck, and chin. It is the most common movement disorder affecting 10 million people in the United States alone, though there have been no improvements in the standard of care in more than 40 years.

We are developing, CAD-1883, a first-in-class selective positive allosteric modulator of SK channels (small conductance, calcium-activated potassium ion channels) in clinical development for the treatment of essential tremor, spinocerebellar ataxia, and other movement disorders.

In preclinical disease models, CAD-1883 has demonstrated the ability to regulate neuronal firing, improve motor control and reduce tremor. CAD-1883 is currently in a Phase 1 dose escalation trial and has been well-tolerated at all doses with only mild, transient adverse effects observed to date. A Phase 2 trial has begun for the treatment of ET.  More information can be found at clinicaltrials.gov.

Spinocerebellar Ataxia Program

SCA is a genetic, degenerative neurological condition that affects approximately 6,000 people in the United States. Patients are readily identified through genetic testing and most often carry genetic abnormalities called “poly-Q expansions,” similar to those found in patients with Huntington’s disease. The disease is progressive and over time, results in ongoing damage to the cerebellum, the part of the brain that regulates motor control and balance.

We are developing, CAD-1883, a first-in-class selective positive allosteric modulator of SK channels (small conductance, calcium-activated potassium ion channels) in clinical development for the treatment of essential tremor, spinocerebellar ataxia, and other movement disorders.

In preclinical disease models, CAD-1883 has demonstrated the ability to regulate neuronal firing, improve motor control and reduce tremor. CAD-1883 is currently in a Phase 1 dose escalation trial and has been well-tolerated at all doses with only mild, transient adverse effects observed to date. The plan is to progress CAD-1883 into a Phase 2 trial for treatment of SCA in the second half of 2019.

Treatment Resistant Depression

Major Depression is the most common psychiatric disorder, affecting 16 million US adults – almost 7% of the population.  Antidepressants typically take up to 6 weeks to provide any relief.  In addition 30% of people with depression continue to experience symptoms after four courses of therapy – their depression is resistant to treatment.  A major breakthrough in clinical neuroscience was the discovery that NMDA receptor antagonists, like ketamine, can rapidly relieve symptoms in these patients, but ketamine causes psychosis-like symptoms and cannot be used outside of a medical unit.  Cadent Therapeutics discovered NMDAr 2B subtype-selective negative allosteric modulators to produce rapid, ketamine-like relief for treatment-resistant patients without ketamine-like side effects.  This program has been licensed to Novartis for clinical development.

Schizophrenia Program

Positive allosteric modulator (PAM) of NMDA channels, a subtype of ion channel receptor activated by glutamate, the most common excitatory neurotransmitter, for the treatment of NMDAr hypofunction in people with schizophrenia.

We have designed our program candidate for the treatment of schizophrenia to positively modulate the N-methyl-D-aspartate receptor (NMDAr) to reverse NMDAr hypofunction in people with schizophrenia and restore cognitive balance. NMDAr hypofunction results in impairment of the brain’s ability to process and differentiate variations and novelty in stimuli, including different types of sounds. Proper functioning of NMDAr in the brain is critical for learning, memory and the ability to form new neuronal connections (neuroplasticity). In people with schizophrenia, these receptors are dysregulated which is related to cognitive impairment. Data have shown that impairment in one measure of sensory and cognitive processing, called Mismatch negativity (MMN), is causally-correlated with cognitive and negative symptoms and global functional deficits in people with schizophrenia, and  is associated with vulnerability to disease progression in clinical high-risk populations.

Preclinical work has demonstrated the ability of our approach to restore MMN in models of NMDAr hypofunction.